Wealth Enhancement Advisory Services LLC Has $17.54 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Wealth Enhancement Advisory Services LLC boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 27.2% during the fourth quarter, Holdings Channel.com reports. The fund owned 22,363 shares of the biopharmaceutical company’s stock after acquiring an additional 4,778 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Regeneron Pharmaceuticals were worth $17,536,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in REGN. CoreCap Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 9.2% during the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock worth $134,000 after purchasing an additional 20 shares in the last quarter. Strait & Sound Wealth Management LLC raised its stake in Regeneron Pharmaceuticals by 3.5% in the third quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock valued at $353,000 after purchasing an additional 21 shares in the last quarter. Parkside Financial Bank & Trust raised its stake in Regeneron Pharmaceuticals by 14.8% in the third quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 21 shares in the last quarter. MAI Capital Management lifted its position in Regeneron Pharmaceuticals by 2.1% during the third quarter. MAI Capital Management now owns 1,028 shares of the biopharmaceutical company’s stock worth $578,000 after purchasing an additional 21 shares during the period. Finally, Independence Bank of Kentucky lifted its position in Regeneron Pharmaceuticals by 7.7% during the third quarter. Independence Bank of Kentucky now owns 308 shares of the biopharmaceutical company’s stock worth $173,000 after purchasing an additional 22 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Up 1.0%

Shares of NASDAQ REGN opened at $749.47 on Thursday. The company has a market cap of $79.23 billion, a price-to-earnings ratio of 18.03, a PEG ratio of 1.99 and a beta of 0.41. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The stock has a 50-day moving average price of $764.28 and a two-hundred day moving average price of $704.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the company posted $12.07 EPS. The firm’s quarterly revenue was up 2.5% compared to the same quarter last year. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.05%.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the transaction, the senior vice president owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 5,274 shares of company stock worth $4,142,738. 7.02% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have commented on REGN shares. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Canaccord Genuity Group upped their price target on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Wells Fargo & Company increased their price target on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a research report on Monday, February 2nd. Bank of America raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and lifted their price objective for the company from $627.00 to $860.00 in a research note on Wednesday, January 7th. Finally, Oppenheimer restated an “outperform” rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $802.27.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Japan approved Dupixent for moderate-to-severe bullous pemphigoid — the first targeted therapy for this indication in that market, based on pivotal data showing substantially higher sustained remission vs. placebo; this expands Dupixent’s label count in Japan and supports additional revenue growth. Press Release
• Positive Sentiment: Analyst and sector pieces highlight a multi-month rally driven by Dupixent growth and pipeline progress, arguing there may still be upside in 2026 as new approvals and indications broaden commercial opportunities. This coverage can attract momentum buyers and analyst upgrades. Article: REGN Soars 28.9% in Six Months
• Neutral Sentiment: Multiple short-interest reports this week show anomalous/zero values (reports cite “significant increase” but list 0 shares and NaN changes). The data appears unreliable and does not provide clear near-term pressure or cover-risk signal. (Watch for corrected filings.)
• Negative Sentiment: EYLEA revenue erosion and intensifying competition remain a headwind: coverage notes Dupixent gains are helping offset losses from the ophthalmology franchise, but competitive pressure in EYLEA’s markets is an ongoing risk to top-line growth. Zacks Article

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.